Glyphase M3 Tablet SR is a sustained-release oral antidiabetic medication combining Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence through reduced gastrointestinal side effects commonly associated with metformin. Glyphase M3 Tablet SR is prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and lifestyle modifications. It is particularly beneficial for patients inadequately controlled on monotherapy or those requiring combination therapy to achieve target glycemic levels. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia is essential. This combination therapy offers a synergistic approach to optimizing glycemic control, reducing the risk of diabetes-related complications.